Related Experiment Video
Updated: Mar 21, 2026

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain
Published on: July 24, 2016
Adverse Events After MMR or MMRV Vaccine in Infants Under Nine Months Old
Emily Jane Woo1, Scott K Winiecki, Deepa Arya
1From the *Office of Biostatistics and Epidemiology and †Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Background:
In the United States, measles is resurging, with more than 700 confirmed cases since January 2014. During measles outbreaks, vaccination as early as at 6 months of age is sometimes recommended for infants who are at risk for exposure.
Methods:
We searched the Vaccine Adverse Event Reporting System for reports of measles, mumps and rubella vaccine combined or measles, mumps, rubella and varicella vaccine combined vaccination in children less than 9 months of age. We performed a clinical assessment of each report and summarized the frequency, range, onset time and severity of adverse events.
Results:
After excluding 346 reports because they were duplicates or because they contained insufficient information about the child's age or vaccine(s), we retained 204 reports in the analysis, including 35 (17%) that were serious. Among the 169 nonserious reports, more than half (88; 52%) described a vaccination error without any adverse event per se. Other nonserious reports described fever, injection reactions and gastrointestinal symptoms. Serious adverse events included developmental disorders, fever and fussiness. There were 44 reports of fever, but only 4 cases began 5-12 days after immunization, the peak risk window. The vast majority of fever reports listed concomitant vaccines, such as diphtheria and tetanus toxoids, acellular or whole-cell pertussis vaccine.
Conclusions:
This review did not identify any major safety concerns. These findings may facilitate discussions about the risks and benefits of vaccinating infants who are potentially exposed to this life-threatening disease.
Insights
Infants under nine months receiving measles vaccines experienced no major safety concerns. Most reports involved vaccination errors or mild side effects like fever, with few serious events noted.
Area of Science:
- Pediatrics
- Vaccinology
- Public Health
Background:
- Measles outbreaks are resurging in the U.S., with over 700 cases reported since January 2014.
- Infants at risk during outbreaks may receive measles vaccination as early as six months of age.
Purpose of the Study:
- To assess the safety of measles, mumps, and rubella (MMR) or measles, mumps, rubella, and varicella (MMRV) vaccines in infants under nine months old.
- To evaluate adverse events reported following vaccination in this age group.
Main Methods:
- Searched the Vaccine Adverse Event Reporting System (VAERS) for vaccination reports in children younger than nine months.
- Conducted clinical assessments of retained reports, summarizing adverse event frequency, range, onset, and severity.
Main Results:
- 204 reports were analyzed after exclusions; 35 (17%) were serious.
- Most nonserious reports (52%) were vaccination errors. Other nonserious events included fever and injection site reactions.
- Serious events included developmental disorders and fever; only 4 fever cases occurred within the peak risk window post-immunization.
Conclusions:
- No significant safety concerns were identified with measles-containing vaccines in infants under nine months.
- Findings support informed discussions on the risks and benefits of early vaccination for infants exposed to measles.
Related Concept Videos
Vaccinations
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Cytomegalovirus Disease
Viral Meningitis
Microorganisms in Medicine and Therapeutics
Myocarditis III: Medical Management

